The transcription factor TBX1 is the major gene implicated in 22q11.2 deletion syndrome. The complex clinical phenotype includes vascular anomalies and a recent report presented new cases of primary lymphedema in 22q11.2DS patients. We have previously shown that Tbx1 activates Vegfr3 gene expression in lymphatic endothelial cells and that this activation is critical for lymphatic vessel development in prenatal mice and for their survival post-natally. Using loss-of-function genetics and transgenesis, we show a strong genetic interaction between Tbx1 and Vegfr3 in cardiac lymphangiogenesis that causes cardiac lymphatic vessel anomalies in compound heterozygotes.
INTRODUCTION
Tbx1 is a major developmental gene whose critical role in lymphangiogenesis has been demonstrated in the mouse (1) . In mice, in the absence of Tbx1, most lymphatic vessels are lost around embryonic day (E)16.5. We have shown that Tbx1 regulates Vegfr3 expression by binding to an intragenic enhancer element in the endogenous Vegfr3 gene. In Tbx1 germline mutants and in ECspecific Tbx1 conditional mutants, Vegfr3 expression in lymphatic ECs is lost between E15.5 and 16.5, which led us to hypothesize that lymphatic vessels in Tbx1 mutants are not maintained because of reduced Vegfr3 expression in lymphatic ECs (1) .
In this study, we have investigated the interplay between Tbx1 and Vegfr3 in cardiac lymphangiogenesis by manipulating the dosage of both genes in ECs. We focused our attention on cardiac lymphangiogenesis because the cardiac lymphatic phenotype is severe in Tbx1 mutants (1) and because cardiac neo-lymphangiogenesis has been implicated in the response to ischemia (2) (3) (4).
In the mouse, the cardiac lymphatic network develops from lymphatic ECs that migrate from extra-cardiac tissues into the heart around E12.5. As embryonic development progresses, an extensive network of sub-epicardial lymphatic vessels forms, extending over the heart from base to apex and covering mainly the left ventricle, both ventrally and dorsally, while fewer lymphatic vessels extend over the right ventricle (5) (2) . The cardiac lymphatic vessel network is complete at postnatal day (P) 15 .
As in other organs, in the heart, the primary role of the lymphatic vessels is to maintain fluid homeostasis and transport immune cells. In the adult heart, tissue fluid absorbed by the lymphatic capillaries drains into two main pre-collector vessels within the heart, that run along the left conal vein dorsally, and the left cardiac vein ventrally, and ultimately into the mediastinal lymph nodes.
Studies in mice show that acute inflammation provokes neolymphangiogenesis, which is important for antigen clearance and for the resolution of inflammation (6)(7). Recently, Klotz et al., showed that cardiac injury (myocardial infarction) provokes a robust neolymphangiogenic response and upregulation of developmental lymphatic genes (Vegfr3, Prox1, Lyve1). Furthermore, post-infarct cardiac function improved after treatment with recombinant Vegf-C (2), suggesting that the Vegf-CVegfr3 axis is important for responding to pathological conditions of the heart.
In this study, we use genetic experiments to demonstrate a strong interaction between Tbx1 and Vegfr3 in cardiac lymphangiogenesis. Increasing endothelial expression of Vegfr3 was sufficient to rescue partially the cardiac lymphatic phenotype in compound heterozygous mutants. However, it did not improve cardiac lymphatic development in Tbx1 homozygous mutants, which lack lymphatic vessels in most tissues, including the heart. Overall, our data suggest that a dosage balance between Tbx1 and Vegfr3 is critical for cardiac lymphatic development.
RESULTS

Tbx1 and Vegfr3 expression overlap in cardiac lymphatics
We used a lacZ reporter allele (8) and monitored Tbx1 expression by -galactosidase (-gal) activity in Tbx1 lacz/+ hearts at E18.5 ( Fig. 1 ). This revealed -gal+ vessel-like structures on the surface of the heart that resembled lymphatic vessels (Fig. 1A, a, a' ). To determine whether these were in fact lymphatic vessels, we immunostained the hearts of wild type littermates with anti-Vegfr3 antibody, which specifically labels lymphatic endothelial cells at this developmental stage (9) . Results indicated that Tbx1 (Fig. 1A , a, a') and Vegfr3 (Fig. 1A , b, b') had near identical expression, indicating that they are co-expressed in most cardiac lymphatic vessels at this stage of development. Note that
Tbx1 is also expressed in the conotruncus (arrow in Fig. 1A , a), as previously reported (10) expression and -gal staining in cardiac lymphatic vessels ( Supplementary Fig. S1 ), indicating that
Tbx1-expressing cells and their descendants populate the majority of cardiac lymphatic vessels.
Furthermore, the lack of -gal+; Vegfr3-negative vessels indicates that in the mouse heart, they contribute exclusively to lymphatic vessels and not to veins and arteries. Cre -activated expression of a fluorescent (GFP) reporter (Fig. 1A , c, c'). Results were comparable to those obtained with the R26R-lacZ reporter.
In the mouse, the first cardiac lymphatic vessels form around E14.5 at the sinus venosus on the dorsal surface of the heart and at the base of the aorta on the ventral surface, from where they extend in a basal to apical direction (5) (2) . We asked what is the earliest time point of Tbx1 expression in cardiac lymphatic vessels? To address this question we performed -gal staining and Lyve1 immunostaining on Tbx1 lacz/+ hearts at E14.5 and E15.5 (anti-Lyve1 labels lymphatic ECs). Results showed that at E14.5 (Fig. 1B, a-d ) and E15.5 (Fig. 1B , e-h), on the dorsal surface of the heart, lymphatic vessels (Lyve1+) at the sinus venosus (Fig. 1B , c, c', g, g') also expressed Tbx1 (-gal+) (arrows in d' and h'). This was less evident on the ventral surface of the E14.5 heart, because Tbx1 is highly expressed in the conotruncus (arrow in b'), where the first ventral lymphatic vessels form (arrows in a'). However, at E15.5, a small network of Tbx1-expressing lymphatic vessels was visible on the ventral surface of the outflow tract (white arrow in f') and heart (black arrow in f'). Thus, we conclude that Tbx1 is expressed in the earliest forming cardiac lymphatic vessels.
Tbx1 is expressed and required in the early phases of cardiac lymphatic development.
In order to pinpoint the critical time requirement for Tbx1 in cardiac lymphatic development, we crossed TgCAGG-CreER TM ;Tbx1 lacZ/+ mice with Tbx1 flox/flox mice and inactivated Tbx1 in a timespecific manner, as previously described (10) . We injected pregnant female mice with a single dose of tamoxifen (TM) at E10.5, E11.5, E12.5, E14.5 and E16.5. We then harvested embryos at E18.5
and analyzed the cardiac lymphatic vessels by Vegfr3 immunostaining (Fig. 1C) . Results showed that after injection of TM at E10.5 ( Fig. 1C, b ) lymphatic vessels were present on the surface of the sinus venosus (arrows in b) but not in the ventricular myocardium. TM injection at E11.5 and E12.5
( Fig. 1C, c, d ) resulted in cardiac lymphatic vessel hypoplasia, while after TM injection at E14.5 and E16.5, the cardiac lymphatic vessel network was indistinguishable from controls ( Fig. 1C , a, e, f).
These results indicate that the critical time requirement for Tbx1 in cardiac lymphangiogenesis is before E14.5. Thus, Tbx1 may be required for the migration of lymphatic ECs into the heart or for their coalescence to form cardiac lymphatic vessels.
Tbx1 and Vegfr3 interact genetically in cardiac lymphatic development
We next tested whether on the ventral surface of the heart where, in most embryos, only a few lymphatic vessels were present around the base of the pulmonary trunk and subpulmonary myocardium (arrow in Fig. 2A , c). The dorsal lymphatic network presented as a reduced network of short, dilated vessels that failed to extend to the apex of the heart (arrow in Fig. 2A , c'). Quantitative analysis confirmed a reduction in the number (Fig. 2C , a, a'), length (Fig. 2C , b, b') and width (Fig. 2C , c, c') of ventral and dorsal cardiac lymphatic vessels in these mutants. Together, these results demonstrate the existence of a strong genetic interaction between Tbx1 and Vegfr3 in cardiac lymphangiogenesis that affects the number and morphology of the lymphatic vessels.
We also examined the intestinal lymphatic vessels of the same embryos by Lyve-1 immunostaining. Results revealed that also in this tissue, there was lymphatic vessel hypoplasia in
Tbx1
Cre/+ ; Vegfr3 flox/+ embryos, in both the membranous mesentery and in the intestinal wall, compared to controls (Tbx1
, Vegfr3 +/-, WT), although the phenotype was more variable than in the heart (Supplementary Fig. S2 ). Thus, we conclude that the genetic interaction between Tbx1 and Vegfr3 is not limited to cardiac lymphatic development.
Generation of a Cre-inducible Vegfr3 transgenic mouse
We have hypothesized that lymphatic vessel hypoplasia in Tbx1 mutants is secondary to reduced Vegfr3 in Tbx1-depleted LECs (1) and here we provide evidence of a genetic interaction between the two genes. We next tested whether increasing Vegfr3 expression in Tbx1-expressing tissues, that includes lymphatic ECs, is sufficient to restore normal lymphatic development in single and compound Tbx1 mutants. We generated a transgenic mouse (named TgVegfr3) that expresses
Vegfr3 upon Cre-induced recombination. For this, we generated a Vegfr3-expressing transgene containing a full length murine Vegfr3 cDNA ( . 3G ) in embryos at E15.5. We observed ectopic expression of the transgenic Vegfr3 protein in the tongue (Fig. 3F, a' ), heart (Fig. 3F, b' , c') and mandibular (masseter) muscle (Fig. 3G, a' ) in E15.5 Tbx1
Cre/+ ; TgVegfr3 embryos but not in Tbx1
Cre/+ (control) embryos (Fig. 3F, a-c, Fig. 3G, a) . Similarly, pERK was expressed in the masseter muscle Results showed that the transgene was able to rescue partially the cardiac lymphatic phenotype of compound heterozygotes, described in detail above and shown in Fig. 2C , c-c' and Fig. 4A , c, c'.
Specifically, on the dorsal surface of the heart of TgVegfr3; Tbx1 Cre/+ ;Vegfr3 flox/+ embryos (Fig. 4A,   d '), the lymphatic vessel network was similar in appearance to that of Tbx1 Cre/+ (control) embryos (Fig. 4A, b' ), being composed of mostly thin, well organized vessels, some of which extended to the apex of the heart. Quantitative analysis confirmed that the length and width of the dorsal lymphatic vessels was fully rescued in TgVegfr3; Tbx1 Cre/+ ;Vegfr3 flox/+ embryos (Fig. 4B, b', c') . In contrast, the number of lymphatic vessels was not rescued by the transgene (Fig. 4B, a' Furthermore, as the number of lymphatic vessels was not rescued by the transgene, The different effects of the transgene on the dorsal versus ventral surface of the heart was puzzling initially, but became more clear when we analyzed TgVegfr3; Tbx1 Cre/+ embryos. In these mutants, the dorsal cardiac lymphatic vessels were indistinguishable from WT and Tbx1 Cre/+ embryos while the ventral surface of the heart lacked lymphatic vessels ( Supplementary Fig. S3 ). This suppressive effect of the transgene on ventral cardiac lymphangiogensis likely accounts for it's inability to rescue the ventral lymphatic hypoplasia caused by combined Tbx1-Vegfr3 haploinsufficiency..
As the transgene was quite effective at rescuing lymphatic anomalies on the dorsal surface of the heart, we tested whether it modified the cardiac lymphatic phenotype of Tbx1 homozygous mutants (TgVegfr3;Tbx1
Cre/lacZ ), with negative results (Table 1 and Supplementary Fig. S3 ).
In conclusion, we propose a model where Tbx1 and Vegfr3 interact in lymphatic ECs to establish a reciprocal gene dosage equilibrium that determines the correct number and morphology of sub-epicardial lymphatic vessels. The absence of lymphatic vessels on the ventral surface of the heart of different genetic mutants used in this study suggests that the Tbx1-Vegfr3 interaction is required prior to, or at the onset of cardiac lymphangiogenesis.
DISCUSSION
Our previous study indicated that Tbx1 regulates lymphatic development through the VegfC- In the future, it would be interesting to determine whether there is a contribution from the secondary heart field, where Tbx1 is highly expressed, and where Tbx1-expressing multi-potent progenitors give rise to ECs that populate the aortic arch arteries and cardiac outflow tract (10), as well as to cardiomyocytes and branchiomeric muscles (15)(16).
We were intrigued by the different response of the ventral and dorsal surfaces of the heart to altered Vegfr3 gene dosage. We have shown here that the genetic interaction between Tbx1 and Vegfr3 is especially evident on the ventral surface of the heart ( Fig. 2A-c) . Furthermore, the capacity of TgVegfr3 to rescue lymphatic anomalies in Tbx1-Vegfr3 compound heterozygotes was limited to the dorsal surface of the heart (Fig. 4d') . Finally, over-expression of Vegfr3 from the TgVegfr3 transgene had a strong effect on the ventral but not dorsal cardiac lymphatic vessels (Fig. 4e, 4e' ). Note that in all three cases, a single copy of Tbx1 (Tbx1
Cre/+
) was inactivated, which alone had no effect on cardiac lymphatics. Together, these results suggest that Tbx1 mutation sensitizes the ventral surface of the heart to altered Vegfr3 gene dosage (mild lymphatic hypertrophy in Vegfr3 +/-mutants affects ventral and dorsal cardiac lymphatic vessels (Fig. 2C) .
What might be the basis of this differential sensitivity? It is not likely to be linked to differences in activation of the transgene as this appeared to be uniform in the dorsal and ventral heart (Fig. 3F, b-c) . In fact, the differential response was also evident in the absence of the transgene, in
Tbx1
Cre/+ ;Vegfr3 flox/+ compound heterozygotes. Other possibilities include, i) differences between lymphatic EC progenitors; Tbx1 may be more highly expressed in ventral progenitors, ii) differences in vessel growth; Tbx1 may be more highly expressed in ventral cardiac lymphatic vessels, and when it is absent they fail to grow, iii) differences in the local environment. Considering the first possibility, studies of early cardiac lymphatic vessel development have shown that they derive from an extracardiac source of Prox1+/Lyve1+ lymphatic ECs that are of mainly venous origin (cardinal vein), which reaches the heart at E12.5-E13 from the mediastinum on the dorsal surface of the heart and from the cardiac outflow tract on the ventral surface (17)(5) (2) These mechanisms may also depend upon Tbx1 dosage. As yet, there are no studies that address the issue in lymphatic vessels, but it is certainly possible that local differences in the molecular milieu on the ventral versus dorsal surfaces of the heart determine a greater sensitivity to the ventral network to interaction, through which TBX1 heterozygosity predisposes to lymphatic anomalies by disrupting the VEGF/C-VEGFR3 signalling pathway. Considering the recent clinical findings and supporting data from mouse models of 22q11.2DS, it would be interesting to determine the frequency of deleterious VEGFR3 variants in 22q11.2DS patients, and establish whether this leads to more severe types of CHD.
MATERIAL AND METHODS
Mouse lines and tissues
The following mouse lines were used: equipped with a camera (Axiocam; Carl Zeiss, Inc.) and the manufacturer's acquisition software.
Images were acquired at 28x magnification.
Quantitative analysis of lymphatic vessel anomalies
We analyzed a minimum of 5 and a maximum of 8 embryos per genotype in all experiments. Threedimensional images were digitally reconstructed from z stacks. For each image, we manually counted all the lymphatic vessels on the dorsal and ventral surfaces of the heart, and we measured the length and area of each vessel. We then calculated the ratio length/area to determine the width of each single vessel. Quantitative analysis was performed using the ImageJ software, (www.uhnresearch.ca/facilities/wcif/imagej).
Statistical analysis
We used the non-parametric Kruskall-Wallis test for the analysis of lymphatic vessels in all experiments with a single exception, namely Vegfr3 +/-vs WT embryos, for which the Mann-Whitney U test was used. We first calculated the mean number of vascular features (number, length, area/length vessels) for each embryo. We then calculated the mean value for the group (same genotype). The latter value was used for the statistical analysis.
Generation of transgenic mouse embryonic stem cells
The starting vector was the pCIG2 plasmid (28) without the nuclear localization sequence of EGFP-CDS that consists of a CMV-IE enhancer, chicken β-actin promoter, MCS, IRES-GFP and rabbit β-globin polyA. A loxP-flanked neomycin resistance cassette was cloned downstream of the β-actin promoter followed by a full-length mouse Vegfr3 cDNA (GeneCoepia). The linearized Vegfr3 transgenic construct, named TgVegfr3, was electroporated into feeder-free E14Tg2A.4 mouse ES cells using the ECM 630 Electro Cell Manipulator System (BTX). Twentyfour hours postelectroporation, the cells were selected in G418 at a final concentration of 250µg/ml. ES cell clones were picked 12 day after plating.
Identification of correctly targeted ES cell clones by southern blotting
Two probes were generated for southern blotting experiments. The first probe distinguished the transgene from the endogenous Vegfr3 gene. It was generated by PCR amplifying a segment of exon 
Generation of transgenic mice
Two correctly targeted ES cell clones were selected for microinjection into mouse blastocysts. Four males chimeras were obtained. These males were bred with black C57BL/6 female mice and three germ line transmissions were obtained. These founders were crossed into the C57BL/6 strain. Mice were genotyped by PCR using DNA extracted from tail biopsies, using following primer pairs: F-5'-ATCGACCTGGCAGACTCCAA-3'; R-5'-GAAAACTGCGATGACGCCAGT-3'.
PCR products were separated on 2% agarose gels.
Western blot analysis
Transfected C2C12 cells were collected 24h after transfection, washed with PBS and lysed in lysis Cre/+ hearts reveals early cardiac lymphatic vessel development (arrows in a', c', e', g'). β-gal staining (right) of E.14. Cre/+ embryos show normal cardiac lymphatic vessels on the dorsal surface and absence of these vessels on the ventral surface. B. Tbx1 homozygous embryos (a, a') lack cardiac lymphatic vessels. Increasing Vegfr3 expression in Tbx1-deficient cells via Tbx1
Cremediated activation of the transgene does not modify this phenotype (b, b').
